Unions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerUS antitrust authorities are coming under pressure from consumer groups and unions to block the proposed $63 billion Share XUnions call on US antitrust regulators to block $63 billion ‘AbbVieGan’ mergerhttps://pharmaphorum.com/news/unions-call-on-us-antitrust-regulators-to-block-63-billion-abbviegan-merger/
The top pharma companies by revenue 2018New analysis from GlobalData has revealed the top 20 pharma companies by revenue for 2018, with Johnson & Share XThe top pharma companies by revenue 2018https://pharmaphorum.com/views-and-analysis/the-top-pharma-companies-by-revenue-2018/
Allergan says it will shed two drugs as AbbVie takeover loomsAllergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead Share XAllergan says it will shed two drugs as AbbVie takeover loomshttps://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/
Allergan pulls breast implants after link to rare cancerAllergan has followed through on an FDA request to carry out a worldwide recall of textured breast implant Share XAllergan pulls breast implants after link to rare cancerhttps://pharmaphorum.com/news/allergan-pulls-breast-implants-after-link-to-rare-cancer/
AbbVie ducks bolt-on trend and agrees Allergan mega-mergerUS drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew Share XAbbVie ducks bolt-on trend and agrees Allergan mega-mergerhttps://pharmaphorum.com/news/abbvie-ducks-bolt-on-trend-and-agrees-allergan-mega-merger/
New paediatric use for Allergan’s biosimilar-threatened BotoxAllergan’s Botox has another clinical use after the FDA granted approval for children with upper limb spasticity. The Share XNew paediatric use for Allergan’s biosimilar-threatened Botoxhttps://pharmaphorum.com/news/new-paediatric-use-for-allergans-biosimilar-threatened-botox/
FDA approves Herceptin biosimilar as US patent expiresThe FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer Share XFDA approves Herceptin biosimilar as US patent expireshttps://pharmaphorum.com/news/fda-approves-herceptin-biosimilar-as-us-patent-expires/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Collaborating to fight NASHEric Hughes, Global Development Unit head at Novartis for Immunology, Hepatology & Dermatology, believes that collaboration is going Share XCollaborating to fight NASHhttps://pharmaphorum.com/r-d/views-analysis-r-d/collaborating-to-fight-nash/
